News

Oncura Fact Sheet

Oncura is a major global presence in the treatment of localized prostate cancer, combining the established and proven option of brachytherapy with the rapidly growing area of cryotherapy. Cryotherapy and brachytherapy currently address the needs of different segments of the prostate cancer treatment market. The combination of the leading products in these two segments will position Oncura as a unique provider of minimally invasive options across the continuum of prostate cancer.

In the United States, 1 in every 6 men will be diagnosed with prostate cancer during their lifetime. Annually, about 200,000 new cases are diagnosed, approximately 75% of these cases represent men with localized prostate cancer. Today, current estimates predict that over $5 billion is spent on treatment.

Oncura provides a global presence in the treatment of prostate cancer, offering physicians and patients a broad choice of minimally invasive treatment options for use in individuals with early, as well as more advanced and recurrent stages of prostate cancer. It also offers the option of cryotherapy for the treatment of kidney cancer.

Headquartered in the United States, Oncura will operate as an independent business of Amersham plc, with Galil holding a minority position of 25 percent. Its Board will consist of three representatives from Amersham and two from Galil. John Jeans, formally President of Amersham’s Therapy business, is Chairman, and Chen Barir, Galil Medical’s Chairman, is vice Chairman.

References:

1. American Cancer Society, Cancer Facts and Figures 2003
2. American Cancer Society, All About Prostate Cancer 2001